Nycomed's Visipaque gains FDA okay

Article

The Food and Drug Administration has approved a new drug applicationfor Hafslund Nycomed's Visipaque, the first in a new generationof dimeric-based x-ray contrast agents to be sold in the U.S.Nycomed, of Oslo, Norway, received the FDA's go-ahead last

The Food and Drug Administration has approved a new drug applicationfor Hafslund Nycomed's Visipaque, the first in a new generationof dimeric-based x-ray contrast agents to be sold in the U.S.Nycomed, of Oslo, Norway, received the FDA's go-ahead last monthto commence U.S. sales.

Nycomed officials are expected to promote the isotonic characteristicsof Visipaque. Compared to conventional contrast media, Visipaquewas shown in clinical trials to reduce the incidence of patientdiscomfort during contrast-enhanced imaging procedures, a Nycomedofficial said. It was approved for general use in a broad rangeof indications.

Dimeric x-ray agents are under scrutiny in Europe, where Scheringhas pulled its Isovist 280 product off the market due to reportsof allergic reactions (SCAN 2/28/96). Nycomed officials say thatVisipaque has not experienced the problems Isovist 280 has encountered,and that the rate of allergic reactions to Visipaque is no higherthan those of other x-ray contrast media. Sales of Visipaque areunder way in 11 European countries, according to Nycomed.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.